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Abstract
An autoimmune hypothesis for the etiology of Meniere’s disease has been proposed. In this study, we focused on
gangliosides as potential antigens for autoantibodies in Meniere’s disease patients. In an attempt to investigate ganglioside
antigens which respond to the serum of patients with Meniere’s disease, we analyzed gangliosides of human acoustic
neurinomas, and used them as antigens to broadly explore gangliosides that react to serum. All the acoustic neurinoma
samples used in the present study showed a similar ganglioside profile on TLC (thin-layer chromatography). For the
microscale ganglioside analysis, a newly developed TLC blotting/secondary ion mass spectrometry (SIMS) system together
with TLC immunostaining method was employed. Most of the ganglioside bands could be analyzed, and they were identified
as GM3, GM2, SPG, GM1a, GD3, S-i (sialyl-i ganglioside) and GD1a. GD1a was the predominant ganglioside and many
neolactoseries gangliosides were recognized by immunological analysis. Next, the immune reactivity of serum samples, from
patients with Meniere’s disease, with the acoustic neurinoma gangliosides was studied by TLC immunostaining. The result
showed that five of 11 patients with Meniere’s disease and one of eight normal subjects reacted with a specific band, which
was identified as S-i by the TLC blotting/SIMS system. The findings of the present study indicate that S-i ganglioside is an
autoantigen and possibly involved in the pathogenesis of Meniere’s disease. ß 2000 Elsevier Science B.V. All rights
reserved.
0925-4439 / 00 / $ ^ see front matter ß 2000 Elsevier Science B.V. All rights reserved.
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Abbreviations: TLC, thin-layer chromatography; HPTLC, high-performance thin-layer chromatography; SIMS, secondary ion mass
spectrometry; PVDF, polyvinylidene di£uoride; MAb, monoclonal antibody; BSA, bovine serum albumin; BBG, bovine brain ganglio-
side; C16:0, hexadecanoic acid; C18:0, octadecanoic acid; C24:0, tetracosanoic acid; d18:1, 2-amino-4-octadecene-1,3-diol ; Hex, hexose;
HexNAc, N-acetylhexosamine; NeuAc, N-acetylneuraminic acid; Cer, ceramide; Gal, galactose; Glc, glucose; GalNAc, N-acetylgalactos-
amine; GlcNAc, N-acetylglucosamine; SPG (sialosyl paragloboside), NeuAc K 2-3Gal L 1-4GlcNAc L 1-3Gal L 1-4Glc L 1-1Cer; S-i
(sialyl-i ganglioside), NeuAc K 2-3Gal L 1-4GlcNAc L 1-3Gal L 1-4GlcNAc L 1-3Gal L 1-4Glc L 1-1Cer; S-I (sialyl-I ganglioside), NeuAc
K 2-3Gal L 1-4GlcNAc L 1-3 (NeuAc K 2-3Gal L 1-4GlcNAc L 1-6) Gal L 1-4GlcNAc L 1-3Gal L 1-4Glc L 1-1Cer; nLc4Cer (para-
globoside), Gal L 1-4GlcNAc L 1-3Gal L 1-4Glc L 1-1Cer; SGPG (sulfoglucuronosyl paragloboside), SO3-3GlcA L 1-3Gal L 1-4GlcNAc L
1-3Gal L 1-4Glc L 1-1Cer; SGLPG (sulfoglucuronosyl lactosaminyl paragloboside), SO3-3GlcA L 1-3Gal L 1-4GlcNAc L 1-3Gal L
1-4GlcNAc L 1-3Gal L 1-4Glc L 1-1Cer
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1. Introduction
Meniere’s disease is an inner ear disease character-
ized by episodic attacks of vertigo, £uctuating cochle-
ar hearing loss, tinnitus, and a feeling of fullness in
the a¡ected ear. The condition underlying Meniere’s
disease has been found to be endolymphatic hydrops
[2]. However, the causes of endolymphatic hydrops
remain unknown, although various hypotheses have
been proposed. Recently, the autoimmune hypothesis
has been proposed and actively discussed [3,4]. This
hypothesis is based on clinical ¢ndings of increases in
blood immune complex levels [5,6], the e⁄cacy of
steroids for hearing loss [3,5,7,8], and the high con-
centration of IgG in endolymph [9], as well as the
basic ¢ndings that endolymphatic hydrops are ob-
served in animals immunized with such antigens as
inner ear tissues [10,11] or collagen [12,13], and that
immune reaction in the endolymphatic sac causes
£uctuating hearing loss [14]. Gangliosides are acidic
glycosphingolipids with sialic acid, and are particu-
larly abundant in the vertebral nervous system. We
have elucidated the involvement of glycosphingoli-
pids in the onset of Guillain^Barre¤ syndrome, an
autoimmune neurological disease [15]. The inner
ear has peripheral sensory cells, and is thought to
include large amounts of gangliosides. We planned
to examine whether autoantibodies against ganglio-
side in the inner ear play a role in the etiology of
Meniere’s disease. However, it is extremely di⁄cult
to collect samples of human inner ear tissues, and
amounts are extremely small even if samples can be
collected. Accordingly, we attempted to take advant-
age of the neoplastic growth of the 8th cranial nerve
(vestibular nerve) in acoustic neurinoma [16]. Neuri-
noma is a benign tumor which originates from
Schwann cells in the peripheral nerve. Despite the
nerve origin of neurinomas, very few studies have
been made on gangliosides in them. We analyzed
gangliosides of human acoustic neurinomas, and
used them as antigens to broadly explore ganglio-
sides that react to the sera of patients with Meniere’s
disease. We used TLC blotting/SIMS [17,18], as well
as a combination of this technique and TLC immu-
nostaining. The purpose of this study is to isolate
and characterize the gangliosides of human acoustic
neurinoma, and to examine the ganglioside antigens
that respond to sera from patients with Meniere’s
disease.
2. Materials and methods
2.1. Materials
Acoustic neurinoma samples were obtained from
seven cases. Surgery was performed at the Depart-
ment of Otolaryngology, Tokyo Medical and Dental
University. All cases were diagnosed histopathologi-
cally as neurinoma (mixed type Antoni A+B).
2.2. Puri¢cation of gangliosides
Acoustic neurinoma samples were suspended in a
mixture of chloroform:methanol (2:1, by vol). Lipids
were extracted by stirring the mixture, and then ¢l-
tering it through a glass wool-packed Pasteur pipette
and evaporating the ¢ltrate to dryness. Total lipid
extracted from the tumor was applied to a DEAE
Sephadex column. Neutral glycolipids and most of
the phospholipids were eluted with a mixture of
chloroform:methanol:water (30:60:8, v/v). Ganglio-
sides were eluted with a mixture of chloroform:
methanol:0.8 N CH3COONa (30:60:8, v/v). The
ganglioside-containing fraction was evaporated to
dryness under reduced pressure in a rotary evapora-
tor, and then dissolved in distilled water. The gan-
glioside solution was applied to a Sep-Pak C18
(Waters Division of Millipore, Milford, MA, USA).
Gangliosides were eluted with methanol after wash-
ing the column with 20^30 ml of water. The obtained
ganglioside fraction was used for further analysis by
TLC and TLC blotting/SIMS analysis, and also for
TLC immunostaining.
2.3. Thin-layer chromatography (TLC)
Gangliosides were separated by TLC on precoated
silica gel Merck 60 plates (HPTLC plates pur-
chased from E. Merck, Darmstadt, Germany). The
BBADIS 61929 19-5-00
A. Ikeda et al. / Biochimica et Biophysica Acta 1501 (2000) 81^9082
developing solvent system was a mixture of chloro-
form:methanol:0.2% aqueous CaCl2 (55:45:10, v/v).
Gangliosides were visualized by spraying the plate
with resorcinol^HCl reagent. Standard gangliosides
GM1a, GD1a, GD1b and GT1b were prepared
from bovine brains. Standard gangliosides GM3,
SPG, S-i and S-I were prepared from human placen-
ta [19]. Standard glycosphingolipids SGPG and
SGLPG were gifts from Dr. T. Ariga (Virginia Com-
monwealth University, VA, USA) [20].
2.4. TLC blotting
TLC blotting was performed as described else-
where [17,18]. Brie£y, gangliosides were applied to
an HPTLC plate and then developed. After develop-
ment, primuline reagent was sprayed over the plate.
The gangliosides on the plate were viewed under ul-
traviolet light at 365 nm. While the plate was illumi-
nated, each ganglioside area was marked with a color
drawing pencil. The HPTLC plate was then im-
mersed for 20 s in a solvent composed of isopropa-
nol:0.2% aqueous CaCl2 :methanol (40:20:7, v/v). It
was then placed on a glass plate, after which a PVDF
membrane sheet (Clear Blott Membrane-P, ATTO
Co. Ltd., Tokyo, Japan) and then a glass micro¢ber
¢lter sheet (GF/A, Whatman International Ltd.,
Maidstone, UK) were placed over the glass plate.
The assemblage was pressed for 15 s with a 180‡C
iron. The PVDF membrane was then separated from
the plate and dried. This method has been referred to
as the ‘Far-Eastern blot’ [18].
2.5. Mass spectrometric analysis of gangliosides
The ganglioside areas on the PVDF membrane
were subjected to SIMS. Each marked ganglioside
area was excised and trimmed to form a circle
2 mm in diameter that ¢t the probe tip of the MS
equipment. One microliter of triethanolamine was
placed on the PVDF membrane. Negative SIMS
spectra were obtained with a Finnigan TSQ70 mass
spectrometer. The ganglioside on the membrane
was bombarded with a Cs beam at 20 kV. The ion
multiplier was 1.5 kV and the conversion diode was
20 kV.
2.6. TLC immunostaining and antibodies
TLC immunostaining was performed as described
elsewhere [21]. The SPS-20 monoclonal antibody spe-
ci¢c for SPG and S-i was a gift from Dr. Y. Kushi
(Tokyo Medical and Dental University) [22]. MAb
speci¢c for GM1a was a gift from Dr. T. Tai (Tokyo
Metropolitan Institute of Medical Science, Tokyo,
Japan). MAb speci¢c for GD3 was a gift from Dr.
J. Portoukalian (INSERM, Lyon, France). The
monoclonal antibody H11, directed to the Gal L
1-4GlcNAc L 1-3Gal of glycosphingolipids, was pre-
pared as described elsewhere [23]. These MAbs
were used as ¢rst antibodies. Horseradish peroxi-
dase-conjugated goat anti-mouse IgM antibody, for
use as a second antibody, was purchased from Cap-
pel Lab (Westchester PA; 1:1000 dilution). A Kon-
ica Immunostain Kit (Konica Co., Inc., Tokyo, Ja-
pan) reagent was used as a staining reagent.
2.7. Sialidase assay on HPTLC plate
This assay was performed as reported elsewhere
[24]. Clostridium perfringens sialidase (type VI) was
purchased from Sigma (St. Louis, MO, USA). Gan-
gliosides obtained from human acoustic neurinoma
were developed on an HPTLC plate, and the entire
plate was incubated with 50 mUnits of C. perfringens
sialidase/ml of 0.1 M acetate bu¡er (pH 5.5) at 37‡C
for 2 h. After incubation, the plate was washed with
phosphate-bu¡ered saline (PBS), and the amount of
nLc4Cer present was determined by immunostaining
with the H11 monoclonal antibody.
2.8. Detection of serum antibodies to gangliosides
Sera from 11 patients with Meniere’s disease were
used in this study. All patients met the diagnostic
criteria of the Ministry of Health and Welfare of
Japan (1974). Sera from eight individuals without
any hearing-related complaints were used as normal
controls.
The serum samples were diluted with 1% BSA con-
taining PBS at 1:25, and mounted on HPTLC plates
on which gangliosides from acoustic neurinomas
were developed. The plates were incubated at 4‡C
overnight and were then washed with PBS. Peroxi-
dase-conjugated anti-human Q-chain and W-chain-spe-
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ci¢c antibody (Tago, Burlingame, CA, USA; 1:1000
dilution with 1% BSA containing PBS) was overlaid
on the plates, and the plates were incubated at room
temperature for 2 h. After washing the plates with
PBS, staining was performed using a Konica Immu-
nostain Kit.
2.9. SGPG and SGLPG in human acoustic
neurinomas
Serum with high antibody titer against SGPG and
SGLPG was gift from Dr. T. Ariga (Virginia Com-
monwealth University, Virginia, USA). TLC immu-
nostaining with serum antibody was performed as
described above. Serum samples were diluted at
1:1000.
3. Results and discussion
3.1. Structural analysis of gangliosides in human
acoustic neurinomas
TLC pro¢les of gangliosides from human acoustic
neurinoma samples are shown in Fig. 1. Similar pat-
terns were obtained in the TLC chromatograms of
gangliosides extracted from seven subjects.
The ganglioside fraction of sample No. 7 in Fig. 1
was subjected to TLC blotting and then used for
SIMS analysis. Seven bands were visualized with ul-
traviolet light after being sprayed with primuline re-
agent. The characteristic SIMS spectra of ganglio-
sides from human acoustic neurinomas are shown
in Fig. 2. The SIMS spectrum clearly showed that
band 1 was GM3 ganglioside with C24:0 and C24:1
fatty acids and a d18:1 long chain base in its ceram-
ide moiety. The spectrum of band 2 indicated that
the ganglioside was GM2 with the same fatty acid
constituents as GM3. The spectra of bands 3 and 4
revealed the same major peals at m/z 1626 and 1628.
The fragmentation pro¢le of band 3 clearly indicated
that the ganglioside has a NeuAc-Hex-HexNAc-Hex-
Hex-Cer structure corresponding to SPG with the
C24:0 and C24:1 fatty acids. While, the SIMS spec-
trum of band 4 showed the appearance of peaks at
m/z 1464 and 1466 corresponding to GM2 fragment
and GM3 fragment peak at m/z 1263, in addition to
the fragments in band 3 spectrum. This fragmenta-
tion pro¢le suggested that band 4 is GM1a with the
C24:0 and C24:1 fatty acids as interpreted in Fig. 2,
band 4. Band 3 was stained by anti-SPG MAb (SPS-
20), and band 4 was stained by anti-GM1a MAb.
Band 3 was thus identi¢ed as SPG, and band 4
as GM1a. The SIMS spectrum in Fig. 2 showed
that band 5 contained two components, one cor-
responding to GM1 and the other to Neu-
Ac(Hex)4(HexNAc)1Cer. The latter ganglioside ap-
pears to be a previously unidenti¢ed component.
The ganglioside with a deprotonated molecule
(1626, 1628) appeared to be GM1b with C24:0 or
C24:1 fatty acid in the ceramide moiety, since its
mobility was a little less than that of standard
GM1a and the band was not immunostained with
Fig. 1. TLC pro¢le of gangliosides from human acoustic neuri-
nomas in seven subjects. Bands were visualized by spraying the
plate with resorcinol reagent. Std.: standard ganglioside. Gan-
glioside nomenclature accords with Svennerholm [1].
C
Fig. 2. Characteristic SIMS spectra of the gangliosides in sample No. 7 in Fig. 1. Left upper part: Gangliosides from standard BBG
and acoustic neurinoma (AN) were separated on an HPTLC plate. Bands were visualized by spraying the plate with resorcinol re-
agent. Arrows show the number of ganglioside bands visualized by ultraviolet light after being sprayed with primuline reagent, and
correspond to those of the SIMS spectrum, respectively. SIMS spectra of (1) band 1, (2) band 2, (3) band 3, (4) band 4, (5) band 5,
(6) band 6, and (7) band 7. The interpretation of fragment ions is shown.
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MAb against GM1a (Fig. 3). The SIMS spectrum
suggested that band 6 was a mixture of S-i with
the C24:0 and C24:1 fatty acid and GD3 with the
C24:0 fatty acid. The peaks at m/z 1993 and 1991
correspond to the deprotonated ion of S-I, and their
fragment peaks are interpreted in the band 6 spec-
trum in Fig. 2. The peak at m/z 1554 in band 6
spectrum corresponds to the deprotonated ion of
GD3 and appearance of the peak at m/z 1263 corre-
sponding to GM3 fragment ion supports the pres-
ence of GD3 ganglioside in band 6. The MAb
against GD3 was used for TLC immunostaining,
and it was recon¢rmed that band 6 contained GD3
(Fig. 3). Band 7 corresponded to GD1a with C24:0
and C24:1 fatty acid as the major component of the
ceramide moiety. GD1a was the most abundant gan-
glioside in all the samples (Fig. 1). Band 7 was the
most abundant ganglioside in all the samples (Fig.
1). The SIMS spectrum of band 7 shows a typical
fragment pro¢le of GD1a. Peaks at m/z 1919 and
1917 show the deprotonated ion of GD1a with the
C24:0 and C24:1 fatty acids in the ceramide moi-
eties. All fragment ions required for GD1a are inter-
preted in the spectrum of band 7. The results are
presented in Fig. 4. Seven gangliosides, GM3,
GM2, SPG, GM1a, GD3, S-i and GD1a, were iden-
ti¢ed in human acoustic neurinomas. The presence of
GM1b was also suggested. In these gangliosides,
C24:0 or C24:1 fatty acid was a major component
rather than C18:0, which is a major fatty acid of
gangliosides in the central nervous system.
The ganglioside composition of the peripheral
nerve di¡ers from that in the central nervous system
[25]. Since human acoustic neurinoma is a peripheral
nerve tumor, we used neuraminidase treatment to
examine the di¡erences between ganglioside species.
The results are shown in Fig. 5. On incubation with
Fig. 3. Immunostaining of human acoustic neurinoma with monoclonal antibody speci¢c for GM1a, SPG and GD3. Gangliosides
from acoustic neurinoma (AN) and standards (BBG and SPG) were separated on an HPTLC plate. 1: Bands were visualized by
spraying the plate with resorcinol reagent. 2: Immunostaining with monoclonal antibodies speci¢c for GM1a (2A), SPG (2B) and
GD3 (2C).
Fig. 4. Characteristic ganglioside pattern in human acoustic
neurinoma. Gangliosides from standard and acoustic neurinoma
(AN) were separated on an HPTLC plate. Bands were visual-
ized by spraying the plate with resorcinol reagent. Sample num-
bers correspond to those of Fig. 1.
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this enzyme, many ganglioside bands corresponding
to N-acetyllactosamine (Gal L 1-4GlcNAc) contain-
ing neutral glycolipids were detected by immuno-
staining with MAb H11. These ¢ndings indicated
that there are many types of N-acetyllactosamine
containing ganglioside in acoustic neurinomas. How-
ever, these N-acetyllactosamines containing ganglio-
sides except for SPG and S-i were only detected by
immunostaining. None of the bovine brain ganglio-
side bands developed on HPTLC plates were de-
tected with MAb H11 after C. perfringens sialidase
treatment (data not shown). These ¢ndings indicate
that acoustic neurinomas contained many neolactos-
eries gangliosides including SPG and S-i, which were
not detected in adult cerebral tissue.
The presence of SGPG and SGLPG was also con-
¢rmed by TLC immunostaining (Fig. 6). These are
also very minor components and very slightly de-
tected by immunostaining.
The ganglioside pattern found in the present study
di¡ered in some respects from that in previous re-
ports [26,27]. We found that neurinomas contained
many types of neolactoseries gangliosides, and signif-
icantly higher proportions of GD1a ganglioside.
Pfei¡er et al. [26] reported that the ganglioside com-
position of acoustic neurinoma was GM3-rich, and
also included GM4, GM2, GM1, GD3 and GD1a.
Shinoura et al. [27] reported that the ganglioside
patterns of neurinoma were divisible into two
groups: GD1a- and GM1-rich type, and GM3-rich
type. Neither study mentioned neolactoseries gan-
gliosides.
3.2. Detection of antibodies to ganglioside antigens in
patients with Meniere’s disease
There have been several studies of the immunore-
activity of sera from patients with Meniere’s disease.
Autoantibodies mentioned in these studies include an
inner ear protein antigen with a molecular weight of
68 000 [28,29], SGLPG [30] and type II collagen [31].
However, none of these autoantibodies has been def-
initely con¢rmed. It has been reported that some of
Fig. 6. TLC immunostaining of the glycosphingolipids with se-
rum from patients with high antibody titers against SGPG and
SGLPG. SGPG, SGLPG and gangliosides from acoustic neuri-
noma (AN) were separated on HPTLC plates. The developing
solvent system was a mixture of chloroform:methanol:0.2%
CaCl2 (55:45:10, v/v). 1: Bands were visualized by spraying the
plate with orcinol reagent. 2: Bands were visualized by spraying
the plate with resorcinol reagent. 3: TLC immunostaining of
the glycosphingolipids with serum from patients with high anti-
body titers against SGPG and SGLPG.
Fig. 5. Detection of gangliosides having Gal L 1-4GlcNAc L
1-3Gal epitope with MAb H11 after C. perfringens sialidase
treatment. Gangliosides from standard and acoustic neurinoma
(AN) were separated on an HPTLC plate. 1: Bands were visu-
alized by spraying the plate with resorcinol reagent. 2: Immu-
nostaining with H11 after sialidase treatment.
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the autoimmune neurological diseases are related to
the gangliosides. Acute [32,33] and chronic [34] pure
motor neuropathy are often associated with the anti-
GM1 antibody [32,34] or anti-GQ1b antibody [33],
and acute [35] and chronic [36] sensory ataxic neuro-
pathies are associated with the autoantibody against
b-series gangliosides.
We examined the immunoreactivity of sera of pa-
tients with Meniere’s disease using gangliosides from
acoustic neurinoma as antigens. TLC immunostain-
ing revealed that ¢ve of 11 patients with Meniere’s
disease and one of eight normal control subjects re-
acted with a speci¢c band. The positive band which
exhibited reactivity on TLC immunostaining was
then subjected to TLC blotting/SIMS. The one spot
yielded a major peak of m/z 1993, corresponding to
the mass of S-i. S-i used as the standard also exhib-
ited reactivity to patient sera on TLC immunostain-
ing (Fig. 7). Yuki et al. reported the occurrence of
anti-S-i antibody in Guillain^Barre¤ syndrome and
chronic in£ammatory demyelinating neuropathy,
but the frequently is not signi¢cant when the disease
control and normal control were compared [37].
It was reported that the oligosaccharide of S-i is
located on the tectorial membrane surface (e.g. Ki-
mura’s membrane), sensory epithelia (outer and in-
ner hair cells) of Corti’s organ, the stria vascularis,
and Reissner’s membrane, in an immunohistological
examination of guinea pig cochleas stained using
monoclonal antibodies [38]. In immuno-£uorescence
testing for identi¢cation of serum antibodies against
human inner ear tissue, patients with Meniere’s dis-
ease or bilateral progressive sensorineural hearing
loss frequently exhibit antibody binding (mainly
IgG class) to parts of the stria vascularis and Reiss-
ner’s membrane [39]. In endolymphatic hydrops, a
distention of Reissner’s membrane is consistently ob-
served [2]. Detection of the antibody responding to
gangliosides in patients with Meniere’s disease may
provide evidence supporting the autoimmune hy-
pothesis for the etiology of Meniere’s disease. Ours
is the ¢rst study to report that Meniere’s disease
patients have antibodies against gangliosides. The
results of the present study suggest that S-i ganglio-
side is involved in the pathogenesis of Meniere’s dis-
ease.
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